摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

3-羟基十四烷酸叔丁酯 | 88271-09-4

中文名称
3-羟基十四烷酸叔丁酯
中文别名
——
英文名称
t-butyl (3RS)-3-hydroxytetradecanoate
英文别名
tert-butyl 3-hydroxytetradecanoate
3-羟基十四烷酸叔丁酯化学式
CAS
88271-09-4
化学式
C18H36O3
mdl
——
分子量
300.482
InChiKey
YZKBUDROMWIDFT-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    6
  • 重原子数:
    21
  • 可旋转键数:
    14
  • 环数:
    0.0
  • sp3杂化的碳原子比例:
    0.94
  • 拓扑面积:
    46.5
  • 氢给体数:
    1
  • 氢受体数:
    3

上下游信息

  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

点击查看最新优质反应信息

文献信息

  • [EN] TOLL-LIKE RECEPTOR 2-AGONISTIC LIPOPEPTIDES, AND METHOD OF MAKING THE SAME<br/>[FR] LIPOPEPTIDES AGONISTES DU RÉCEPTEUR 2 DE TYPE TOLL, ET PROCÉDÉ DE FABRICATION DE CEUX-CI
    申请人:UNIV KANSAS
    公开号:WO2014113634A1
    公开(公告)日:2014-07-24
    The present disclosure is directed to a novel class of toll-like receptor 2-agnonistic (TLR2) lipopeptide compounds having specific structures, and synthetic methods of making the compounds. These compounds provide high potency of agonistic activities with human, other than murine, TLR2, and are useful as vaccine adjuvants. Vaccines are perhaps one of the most successful medical interventions against infectious disease.
    本公开涉及一类新型的特定结构的类胜肽化的类Toll样受体2激动剂(TLR2)脂肽化合物,以及制备这些化合物的合成方法。这些化合物在人类TLR2中具有高激动活性,并可用作疫苗佐剂。疫苗可能是针对传染病最成功的医学干预之一。
  • N-Acylpeptide compound, processes for the preparation thereof and the
    申请人:Fujisawa Pharmaceutical Co., Ltd.
    公开号:US04436726A1
    公开(公告)日:1984-03-13
    This invention relates to new N-acylpeptide compounds of immunological activity, said compounds being of the formula: ##EQU1## wherein R.sup.1 and R.sup.2 are each alkyl or alkenyl; R.sup.3 is hydrogen, lower alkyl, hydroxy(lower)alkyl, heterocyclic(lower)alkyl or ar(lower)alkyl, wherein the aryl moiety may have hydroxy or protected hydroxy; R.sup.4 is carboxy, esterified carboxy, carboxy(lower)alkyl or esterified carboxy(lower)alkyl; X is bond or lower alkylene; Y is lower alkylene or lower alkylidene; and n is an integer of 0 to 1; or its pharmaceutically acceptable salt.
    这项发明涉及具有免疫活性的新的N-酰肽化合物,所述化合物的结构如下:其中R^1和R^2分别是烷基或烯基;R^3是氢、较低烷基、羟基(较低)烷基、杂环(较低)烷基或芳基(较低)烷基,其中芳基部分可能具有羟基或保护羟基;R^4是羧基、酯化羧基、羧基(较低)烷基或酯化羧基(较低)烷基;X是键或较低烷基;Y是较低烷基或较低亚甲基;n是0至1的整数;或其药用可接受盐。
  • 1,4-Diaminocyclitol derivatives
    申请人:Fujisawa Pharmaceutical Co., Ltd.
    公开号:US04504472A1
    公开(公告)日:1985-03-12
    This invention relates to novel, 1,4-diaminocyclitol derivatives of antimicrobial and immunostimulating activity of the formula: ##STR1## wherein X.sup.1, X.sup.2 and X.sup.3 are each amino or protected amino, X.sup.4 is hydrogen or hydroxy, R.sup.1 is hydrogen or lower alkyl, and R.sup.2 is higher alkanoyl permissably substituted with hydroxy, amino, azido, epoxy, protected hydroxy or protected amino, or higher alkenoyl, or higher alkylcarbanoyl, and pharmaceutically acceptable salts thereof.
    本发明涉及一种新型的1,4-二氨基环己糖衍生物,具有抗微生物和免疫刺激活性,其化学式为:##STR1##其中,X.sup.1、X.sup.2和X.sup.3分别为氨基或受保护的氨基,X.sup.4为氢或羟基,R.sup.1为氢或低碳基,R.sup.2为高碳酰基,可被取代为羟基、氨基、偶氮、环氧、受保护的羟基或受保护的氨基,或为高烯酰基、高烷基羧酰基,以及其药学上可接受的盐。
  • TOLL-LIKE RECEPTOR 2-AGONISTIC LIPOPEPTIDES, AND METHOD OF MAKING THE SAME
    申请人:UNIVERSITY OF KANSAS
    公开号:US20150337009A1
    公开(公告)日:2015-11-26
    The present disclosure is directed to a novel class of toll-like receptor 2-agonistic (TLR2) lipopeptide compounds having specific structures, and synthetic methods of making the compounds. These compounds provide high potency of agonistic activities with human, other than murine, TLR2, and are useful as vaccine adjuvants. Vaccines are perhaps one of the most successful medical interventions against infectious disease.
    本公开涉及一种新型的具有特定结构的Toll样受体2-激动剂(TLR2)脂肽化合物及其合成方法。这些化合物在人类(而非小鼠)的TLR2上具有高效的激动活性,并可用作疫苗佐剂。疫苗可能是预防传染病最成功的医疗干预措施之一。
  • Duthaler, Rudolf O.; Herold, Peter; Lottenbach, Willy, Angewandte Chemie, 1989, vol. 101, # 4, p. 490 - 491
    作者:Duthaler, Rudolf O.、Herold, Peter、Lottenbach, Willy、Oertle, Konrad、Riediker, Martin
    DOI:——
    日期:——
查看更多